U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Cervical Adenocarcinoma

MedGen UID:
1793239
•Concept ID:
C5556798
•
Neoplastic Process

Definition

Cervical adenocarcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Cervical Adenocarcinoma

Professional guidelines

PubMed

Camrelizumab and metronomic capecitabine for patients with treatment-refractory solid tumors (McCREST trial).
Zhou C, Shangguan C, Shi M, Xi W, Wu J, Yang H, Guo L, Cai Q, Shi Y, Liu J, Zhang J
Future Oncol 2022 Jul;18(23):2495-2503. Epub 2022 Jun 15 doi: 10.2217/fon-2021-1579. PMID: 35703115
Chapter XX Antiviral Treatment and Cancer Control.
Shih WL, Fang CT, Chen PJ
Recent Results Cancer Res 2021;217:325-354. doi: 10.1007/978-3-030-57362-1_13. PMID: 33200371
Impact of Histopathological Risk Factors on the Treatment of Stage IB-IIB Uterine Cervical Cancer.
Shimada M, Tokunaga H, Kigawa J, Yaegashi N
Tohoku J Exp Med 2020 Dec;252(4):339-351. doi: 10.1620/tjem.252.339. PMID: 33311005

Recent clinical studies

Etiology

Aggressive Subtypes of Papillary Thyroid Carcinoma Smaller Than 1 cm.
Lee JS, Lee JS, Yun HJ, Kim SM, Chang H, Lee YS, Chang HS, Park CS
J Clin Endocrinol Metab 2023 May 17;108(6):1370-1375. doi: 10.1210/clinem/dgac739. PMID: 36546348Free PMC Article
Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, Paparo SR, Benvenga S, Antonelli A
Semin Cancer Biol 2022 Feb;79:180-196. Epub 2020 Nov 26 doi: 10.1016/j.semcancer.2020.11.013. PMID: 33249201
Impact of Histopathological Risk Factors on the Treatment of Stage IB-IIB Uterine Cervical Cancer.
Shimada M, Tokunaga H, Kigawa J, Yaegashi N
Tohoku J Exp Med 2020 Dec;252(4):339-351. doi: 10.1620/tjem.252.339. PMID: 33311005
The prognostic implications from molecular testing of thyroid cancer.
Ozgursoy OB, Eisele DW, Tufano RP
Otolaryngol Clin North Am 2014 Aug;47(4):595-607. doi: 10.1016/j.otc.2014.04.010. PMID: 25041960
Laparoscopic total esophagectomy.
Swanstrom LL, Hansen P
Arch Surg 1997 Sep;132(9):943-7; discussion 947-9. doi: 10.1001/archsurg.1997.01430330009001. PMID: 9301605

Diagnosis

A register-based study: cough - a frequent phenomenon in the adult population.
Backer V, Porsborg A, Hansen V, Skjold T, Schmid JM, Kehlet M, Torp-Pedersen C, Aasbjerg K
BMC Pulm Med 2022 Nov 19;22(1):426. doi: 10.1186/s12890-022-02228-z. PMID: 36401236Free PMC Article
AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1(+) CD8 T cells.
Li H, Liu Z, Liu L, Zhang H, Han C, Girard L, Park H, Zhang A, Dong C, Ye J, Rayford A, Peyton M, Li X, Avila K, Cao X, Hu S, Alam MM, Akbay EA, Solis LM, Behrens C, Hernandez-Ruiz S, Lu W, Wistuba I, Heymach JV, Chisamore M, Micklem D, Gabra H, Gausdal G, Lorens JB, Li B, Fu YX, Minna JD, Brekken RA
Cell Rep Med 2022 Mar 15;3(3):100554. doi: 10.1016/j.xcrm.2022.100554. PMID: 35492873Free PMC Article
Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, Paparo SR, Benvenga S, Antonelli A
Semin Cancer Biol 2022 Feb;79:180-196. Epub 2020 Nov 26 doi: 10.1016/j.semcancer.2020.11.013. PMID: 33249201
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer.
Montironi R, Cimadamore A, Lopez-Beltran A, Scarpelli M, Aurilio G, Santoni M, Massari F, Cheng L
Cells 2020 Apr 25;9(5) doi: 10.3390/cells9051073. PMID: 32344931Free PMC Article
The prognostic implications from molecular testing of thyroid cancer.
Ozgursoy OB, Eisele DW, Tufano RP
Otolaryngol Clin North Am 2014 Aug;47(4):595-607. doi: 10.1016/j.otc.2014.04.010. PMID: 25041960

Therapy

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
Javle M, King G, Spencer K, Borad MJ
Oncologist 2023 Nov 2;28(11):928-943. doi: 10.1093/oncolo/oyad149. PMID: 37390492Free PMC Article
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
Subbiah V, Iannotti NO, Gutierrez M, Smith DC, Féliz L, Lihou CF, Tian C, Silverman IM, Ji T, Saleh M
Ann Oncol 2022 May;33(5):522-533. Epub 2022 Feb 14 doi: 10.1016/j.annonc.2022.02.001. PMID: 35176457
Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, Paparo SR, Benvenga S, Antonelli A
Semin Cancer Biol 2022 Feb;79:180-196. Epub 2020 Nov 26 doi: 10.1016/j.semcancer.2020.11.013. PMID: 33249201
NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake.
Lee YA, Lee H, Im SW, Song YS, Oh DY, Kang HJ, Won JK, Jung KC, Kwon D, Chung EJ, Hah JH, Paeng JC, Kim JH, Choi J, Kim OH, Oh JM, Ahn BC, Wirth LJ, Shin CH, Kim JI, Park YJ
J Clin Invest 2021 Sep 15;131(18) doi: 10.1172/JCI144847. PMID: 34237031Free PMC Article
Copanlisib: First Global Approval.
Markham A
Drugs 2017 Dec;77(18):2057-2062. doi: 10.1007/s40265-017-0838-6. PMID: 29127587

Prognosis

Pathogenesis and signaling pathways related to iodine-refractory differentiated thyroid cancer.
Zhao S, Zhao Y, Zhao Y, Wang G
Front Endocrinol (Lausanne) 2023;14:1320044. Epub 2024 Jan 19 doi: 10.3389/fendo.2023.1320044. PMID: 38313845Free PMC Article
Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, Paparo SR, Benvenga S, Antonelli A
Semin Cancer Biol 2022 Feb;79:180-196. Epub 2020 Nov 26 doi: 10.1016/j.semcancer.2020.11.013. PMID: 33249201
Single-cell transcriptomic analysis of the tumor ecosystems underlying initiation and progression of papillary thyroid carcinoma.
Pu W, Shi X, Yu P, Zhang M, Liu Z, Tan L, Han P, Wang Y, Ji D, Gan H, Wei W, Lu Z, Qu N, Hu J, Hu X, Luo Z, Li H, Ji Q, Wang J, Zhang X, Wang YL
Nat Commun 2021 Oct 18;12(1):6058. doi: 10.1038/s41467-021-26343-3. PMID: 34663816Free PMC Article
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer.
Montironi R, Cimadamore A, Lopez-Beltran A, Scarpelli M, Aurilio G, Santoni M, Massari F, Cheng L
Cells 2020 Apr 25;9(5) doi: 10.3390/cells9051073. PMID: 32344931Free PMC Article
The prognostic implications from molecular testing of thyroid cancer.
Ozgursoy OB, Eisele DW, Tufano RP
Otolaryngol Clin North Am 2014 Aug;47(4):595-607. doi: 10.1016/j.otc.2014.04.010. PMID: 25041960

Clinical prediction guides

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
Javle M, King G, Spencer K, Borad MJ
Oncologist 2023 Nov 2;28(11):928-943. doi: 10.1093/oncolo/oyad149. PMID: 37390492Free PMC Article
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study.
Simonelli M, Garralda E, Eskens F, Gil-Martin M, Yen CJ, Obermannova R, Chao Y, Lonardi S, Melichar B, Moreno V, Yu ML, Bongiovanni A, Calvo E, Rottey S, Machiels JP, Gonzalez-Martin A, Paz-Ares L, Chang CL, Mason W, Lin CC, Reardon DA, Vieito M, Santoro A, Meng R, Abbadessa G, Menas F, Lee H, Liu Q, Combeau C, Ternes N, Ziti-Ljajic S, Massard C
ESMO Open 2022 Oct;7(5):100562. Epub 2022 Aug 18 doi: 10.1016/j.esmoop.2022.100562. PMID: 35987165Free PMC Article
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors.
Sanborn RE, Pishvaian MJ, Callahan MK, Weise A, Sikic BI, Rahma O, Cho DC, Rizvi NA, Sznol M, Lutzky J, Bauman JE, Bitting RL, Starodub A, Jimeno A, Reardon DA, Kaley T, Iwamoto F, Baehring JM, Subramaniam DS, Aragon-Ching JB, Hawthorne TR, Rawls T, Yellin M, Keler T
J Immunother Cancer 2022 Aug;10(8) doi: 10.1136/jitc-2022-005147. PMID: 35940825Free PMC Article
AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1(+) CD8 T cells.
Li H, Liu Z, Liu L, Zhang H, Han C, Girard L, Park H, Zhang A, Dong C, Ye J, Rayford A, Peyton M, Li X, Avila K, Cao X, Hu S, Alam MM, Akbay EA, Solis LM, Behrens C, Hernandez-Ruiz S, Lu W, Wistuba I, Heymach JV, Chisamore M, Micklem D, Gabra H, Gausdal G, Lorens JB, Li B, Fu YX, Minna JD, Brekken RA
Cell Rep Med 2022 Mar 15;3(3):100554. doi: 10.1016/j.xcrm.2022.100554. PMID: 35492873Free PMC Article
Laparoscopic total esophagectomy.
Swanstrom LL, Hansen P
Arch Surg 1997 Sep;132(9):943-7; discussion 947-9. doi: 10.1001/archsurg.1997.01430330009001. PMID: 9301605

Recent systematic reviews

Will targeted therapy hold its promise? An evidence-based review.
Murdoch D, Sager J
Curr Opin Oncol 2008 Jan;20(1):104-11. doi: 10.1097/CCO.0b013e3282f44b12. PMID: 18043264

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...